| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 20.07B | $ 16.75B | $ 14.24B | $ 12.68B | $ 11.89B |
| Gross Profit | $ 13.85B | $ 10.27B | $ 8.83B | $ 7.71B | $ 7.46B |
| Operating Income | $ 3.97B | $ 2.63B | $ 2.18B | $ 1.82B | $ 1.92B |
| EBITDA | $ 5.10B | $ 3.94B | $ 3.45B | $ 2.74B | $ 2.52B |
| Net Income | $ 2.89B | $ 1.85B | $ 1.59B | $ 698.00M | $ 1.04B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 2.04B | $ 414.00M | $ 865.00M | $ 928.00M | $ 1.93B |
| Total Assets | $ 43.67B | $ 39.40B | $ 35.14B | $ 32.47B | $ 32.23B |
| Total Debt | $ 12.42B | $ 11.15B | $ 9.49B | $ 9.28B | $ 9.45B |
| Net Debt | $ 10.37B | $ 10.73B | $ 8.63B | $ 8.35B | $ 7.53B |
| Total Liabilities | $ 19.20B | $ 17.39B | $ 15.61B | $ 14.90B | $ 15.61B |
| Stockholders' Equity | $ 24.23B | $ 21.77B | $ 19.28B | $ 17.57B | $ 16.62B |
| Cash Flow | |||||
| Free Cash Flow | $ 3.66B | $ 2.65B | $ 1.70B | $ 914.00M | $ 1.32B |
| Operating Cash Flow | $ 4.53B | $ 3.44B | $ 2.50B | $ 1.53B | $ 1.87B |
| Investing Cash Flow | $ -2.64B | $ -5.69B | $ -2.57B | $ -2.01B | $ -1.60B |
| Financing Cash Flow | $ -395.00M | $ 1.81B | $ 5.00M | $ -548.00M | $ -95.00M |
Boston Scientific (CH:BSX)
:BSX
